How I manage pregnant patients who are alloimmunized to RBC antigens Available to Purchase

2.

Hendrickson

JE

,

Tormey

CA

.

Understanding red blood cell alloimmunization triggers

.

Hematology Am Soc Hematol Educ Program

.

2016

;

2016

(

1

):

446

-

451

.

3.

Webb

J

,

Delaney

M

.

Red blood cell alloimmunization in the pregnant patient

.

Transfus Med Rev

.

2018

;

32

(

4

):

213

-

219

.

4.

Cohn

C

,

Delaney

M

,

Johnson

ST

, et al. Technical Manual. 21st ed..

Association for the Advancement of Blood and Biotherapies

;

2023

.

5.

Lappen

JR

,

Stark

S

,

Gibson

KS

,

Prasad

M

,

Bailit

JL

.

Intravenous drug use is associated with alloimmunization in pregnancy

.

Am J Obstet Gynecol

.

2016

;

215

(

3

):

344.e1-6

.

6.

Australian and New Zealand Society of Blood Transfusion Ltd

. Guidelines for Transfusion and Immunohaematology Laboratory Practice. 1st edition revised.

January 2020

.

7.

White

J

,

Qureshi

H

,

Massey

E

, et al.

Guideline for blood grouping and red cell antibody testing in pregnancy

.

Transfus Med

.

2016

;

26

(

4

):

246

-

263

.

8.

National Institute for Health and Care Excellence

.

NICE Guideline: Antenatal Care

.

2021

.

9.

Pal

M

,

Williams

B

.

Prevalence of maternal red cell alloimmunisation: a population study from Queensland, Australia

.

Pathology

.

2015

;

47

(

2

):

151

-

155

.

10.

Ainley

L

,

Jardim

JR

,

Tan

J

, et al.

Prevalence of maternal alloantibodies in a large teaching hospital and their impact on outcomes of fetuses/neonates

.

Transfus Med

.

2017

;

27

(

3

):

228

-

230

.

11.

Koelewijn

JM

,

Vrijkotte

TG

,

van der Schoot

CE

,

Bonsel

GJ

,

de Haas

M

.

Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands

.

Transfusion

.

2008

;

48

(

5

):

941

-

952

.

12.

Rahimi-Levene

N

,

Chezar

J

,

Yahalom

V

;

Israeli HDFN Study Group Investigators

.

Red blood cell alloimmunization prevalence and hemolytic disease of the fetus and newborn in Israel: a retrospective study

.

Transfusion

.

2020

;

60

(

11

):

2684

-

2690

.

13.

Moinuddin

I

,

Fletcher

C

,

Millward

P

.

Prevalence and specificity of clinically significant red cell alloantibodies in pregnant women - a study from a tertiary care hospital in Southeast Michigan

.

J Blood Med

.

2019

;

10

:

283

-

289

.

14.

Altuntas

N

,

Yenicesu

I

,

Himmetoglu

O

, et al.

The risk assessment study for hemolytic disease of the fetus and newborn in a University Hospital in Turkey

.

Transfus Apher Sci

.

2013

;

48

(

3

):

377

-

380

.

15.

Olayanju

AO

,

Chris

NI

,

Emmanuel

AE

,

Oyetunde

AB

,

Adebisi

KY

,

Okolo

CS

.

Prevalence of alloantibodies associated with haemolytic disease of the fetus and newborn in pregnant women at the Ekiti State University Teaching Hospital, Ado-Ekiti, Southwest Nigeria

.

Afr J Reprod Health

.

2023

;

27

(

6s

):

70

-

78

.

16.

Luken

JS

,

Folman

CC

,

Lukens

MV

, et al.

Reduction of anti-K-mediated hemolytic disease of newborns after the introduction of a matched transfusion policy: a nation-wide policy change evaluation study in the Netherlands

.

Transfusion

.

2021

;

61

(

3

):

713

-

721

.

17.

Delaney

M

,

Wikman

A

,

van de Watering

L

, et al.

Blood Group Antigen Matching Influence on Gestational Outcomes (AMIGO) study

.

Transfusion

.

2017

;

57

(

3

):

525

-

532

.

18.

Van Kim

CL

,

Colin

Y

,

Cartron

JP

.

Rh proteins: key structural and functional components of the red cell membrane

.

Blood Rev

.

2006

;

20

(

2

):

93

-

110

.

19.

Slootweg

YM

,

Lindenburg

IT

,

Koelewijn

JM

,

Van Kamp

IL

,

Oepkes

D

,

De Haas

M

.

Predicting anti-Kell-mediated hemolytic disease of the fetus and newborn: diagnostic accuracy of laboratory management

.

Am J Obstet Gynecol

.

2018

;

219

(

4

):

393.e1

-

393.e8

.

20.

Broadberry

RE

,

Lin

M

.

The distribution of the MiIII (Gp.Mur) phenotype among the population of Taiwan

.

Transfus Med

.

1996

;

6

(

2

):

145

-

148

.

21.

Poole

J

,

King

MJ

,

Mak

KH

,

Liew

YW

,

Leong

S

,

Chua

KM

.

The MiIII phenotype among Chinese donors in Hong Kong: immunochemical and serological studies

.

Transfus Med

.

1991

;

1

(

3

):

169

-

175

.

22.

Heathcote

DJ

,

Carroll

TE

,

Flower

RL

.

Sixty years of antibodies to MNS system hybrid glycophorins: what have we learned?

.

Transfus Med Rev

.

2011

;

25

(

2

):

111

-

124

.

23.

Wu

KH

,

Chang

JG

,

Lin

M

, et al.

Hydrops foetalis caused by anti-Mur in first pregnancy--a case report

.

Transfus Med

.

2002

;

12

(

5

):

325

-

327

.

24.

Royal College of Obstetricians and Gynaecologists

.

Green-Top Guideline 65: The Management of Women With Red Cell Antibodies in Pregnancy

.

RCoOaGG (Britain)

;

2014

.

25.

Choudhuri

J

,

Chacko

M

,

Kuruvilla

A

, et al.

Clinical impact and prevalence of IgG1 and IgG3 subclasses in antenatal alloimmunized women: experience from a tertiary medical centre in South India

.

ISBT Sci Ser

.

2016

;

11

(

1

):

58

-

61

.

26.

Mari

G

,

Norton

ME

, et al;

Society for Maternal-Fetal Medicine SMFM Electronic address pubs@smfmorg

.

Society for Maternal-Fetal Medicine (SMFM) Clinical Guideline #8: the fetus at risk for anemia--diagnosis and management

.

Am J Obstet Gynecol

.

2015

;

212

(

6

):

697

-

710

.

27.

Hyland

CA

,

O'Brien

H

,

Flower

RL

,

Gardener

GJ

.

Non-invasive prenatal testing for management of haemolytic disease of the fetus and newborn induced by maternal alloimmunisation

.

Transfus Apher Sci

.

2020

;

59

(

5

):

102947

.

28.

Ginige

S

,

Daly

J

,

Hyland

C

, et al.

The role of non-invasive prenatal testing (NIPT) for fetal blood group typing in Australia

.

Aust N Z J Obstet Gynaecol

.

2022

;

62

(

1

):

33

-

36

.

29.

Samson

J

,

Block

D

,

Mari

G

.

Middle cerebral artery Doppler for managing fetal anemia

.

Clin Obstet Gynecol

.

2010

;

53

(

4

):

851

-

857

.

30.

Martinez-Portilla

RJ

,

Lopez-Felix

J

,

Hawkins-Villareal

A

, et al.

Performance of fetal middle cerebral artery peak systolic velocity for prediction of anemia in untransfused and transfused fetuses: systematic review and meta-analysis

.

Ultrasound Obstet Gynecol

.

2019

;

54

(

6

):

722

-

731

.

31.

Fox

C

,

Martin

W

,

Somerset

DA

,

Thompson

PJ

,

Kilby

MD

.

Early intraperitoneal transfusion and adjuvant maternal immunoglobulin therapy in the treatment of severe red cell alloimmunization prior to fetal intravascular transfusion

.

Fetal Diagn Ther

.

2008

;

23

(

2

):

159

-

163

.

32.

Zwiers

C

,

Lindenburg

ITM

,

Klumper

FJ

,

de Haas

M

,

Oepkes

D

,

Van Kamp

IL

.

Complications of intrauterine intravascular blood transfusion: lessons learned after 1678 procedures

.

Ultrasound Obstet Gynecol

.

2017

;

50

(

2

):

180

-

186

.

33.

Garabedian

C

,

Rakza

T

,

Thomas

D

, et al.

Neonatal outcome after fetal anemia managed by intrauterine transfusion

.

Eur J Pediatr

.

2015

;

174

(

11

):

1535

-

1539

.

34.

Connan

K

,

Kornman

L

,

Savoia

H

,

Palma-Dias

R

,

Rowlands

S

.

IVIG - is it the answer? Maternal administration of immunoglobulin for severe fetal red blood cell alloimmunisation during pregnancy: a case series

.

Aust N Z J Obstet Gynaecol

.

2009

;

49

(

6

):

612

-

618

.

35.

Vlachodimitropoulou

E

,

Lo

TK

,

Bambao

C

, et al.

Intravenous immunoglobulin in the management of severe early onset red blood cell alloimmunisation

.

Br J Haematol

.

2023

;

200

(

1

):

100

-

106

.

36.

Zwiers

C

,

van der Bom

JG

,

van Kamp

IL

, et al.

Postponing early intrauterine transfusion with intravenous immunoglobulin treatment; the PETIT study on severe hemolytic disease of the fetus and newborn

.

Am J Obstet Gynecol

.

2018

;

219

(

3

):

291.e1

-

291.e9

.

37.

Stiehm

ER

.

Adverse effects of human immunoglobulin therapy

.

Transfus Med Rev

.

2013

;

27

(

3

):

171

-

178

.

38.

Castleman

JS

,

Moise

KJ

,

Kilby

MD

.

Medical therapy to attenuate fetal anaemia in severe maternal red cell alloimmunisation

.

Br J Haematol

.

2021

;

192

(

3

):

425

-

432

.

39.

Capraru

A

,

Raio

L

,

Müller

M

, et al.

Immunoadsorption, intravenous immunoglobulins and rituximab (IIR): successful new treatment approach for severe anti K- alloimmunisation during pregnancy [abstract]

.

Blood

.

2020

;

136

(

suppl 1

):

16

-

17

.

40.

Ling

LE

,

Hillson

JL

,

Tiessen

RG

, et al.

M281, an anti-FcRn antibody: pharmacodynamics, pharmacokinetics, and safety across the full range of IgG reduction in a first-in-human study

.

Clin Pharmacol Ther

.

2019

;

105

(

4

):

1031

-

1039

.

41.

Zuercher

AW

,

Spirig

R

,

Baz Morelli

A

,

Rowe

T

,

Käsermann

F

.

Next-generation Fc receptor-targeting biologics for autoimmune diseases

.

Autoimmun Rev

.

2019

;

18

(

10

):

102366

.